Pramlintide acetate

醋酸普兰林肽

Report date: 2025/12/02 20:00:12
NMEFirst In Class

Base Information

Drug NamePramlintide acetate
Drug Alias Name普兰林肽醋酸盐pramlintide普兰林肽pramlintidumTripro-amylin +[12] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionCalcitonin receptor agonists
TargetsCalcitonin receptor
Therapy Area/IndicationsCognitive DysfunctionOverweightObesity +[8] 
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2005/03/16
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAmylin PharmaceuticalBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBoston UniversityHangzhou Heze Pharmaceutical Technology Co Ltd
Inactive CompaniesAmylin Pharmaceuticals LlcH Lee Moffitt Cancer Center & Research InstituteAstrazeneca Plc +[7] 
Active IndicationsCognitive DysfunctionDiabetes MellitusAlzheimer Disease
Inactive IndicationsOverweightObesityDiabetes Mellitus, Type 2 +[5] 

Other Information

ATC CodeA10BX05
Related LinksWikipediaDrugBankKEGG